2022
DOI: 10.1016/j.compbiomed.2022.105711
|View full text |Cite
|
Sign up to set email alerts
|

A radiation resistance related index for biochemical recurrence and tumor immune environment in prostate cancer patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
10
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(10 citation statements)
references
References 31 publications
0
10
0
Order By: Relevance
“…According to the projections provided by Alliance of Genome Resources, ZNF695 may enable DNAbinding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity, and is predicted to be involved in regulation of transcription (https://www.alliancegenome.org/ gene/HGNC:30954#summary). Ke ZB et al found that ZNF695 is an important marker of radiotherapy resistance in prostate cancer (42), and is closely related to the proliferation, invasion and migration of prostate cancer cells, which may be an important factor affecting the microenvironment of prostate cancer (42,43).Takahashi T et al found that methylation of ZNF695 is an important factor affecting the chemotherapeutic resistance of esophageal squamous cell carcinoma (44). Some studies have also found that ZNF695 is closely related to the prognosis of breast cancer (45) and ovarian cancer (46).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…According to the projections provided by Alliance of Genome Resources, ZNF695 may enable DNAbinding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity, and is predicted to be involved in regulation of transcription (https://www.alliancegenome.org/ gene/HGNC:30954#summary). Ke ZB et al found that ZNF695 is an important marker of radiotherapy resistance in prostate cancer (42), and is closely related to the proliferation, invasion and migration of prostate cancer cells, which may be an important factor affecting the microenvironment of prostate cancer (42,43).Takahashi T et al found that methylation of ZNF695 is an important factor affecting the chemotherapeutic resistance of esophageal squamous cell carcinoma (44). Some studies have also found that ZNF695 is closely related to the prognosis of breast cancer (45) and ovarian cancer (46).…”
Section: Discussionmentioning
confidence: 99%
“…Ke ZB et al. found that ZNF695 is an important marker of radiotherapy resistance in prostate cancer ( 42 ), and is closely related to the proliferation, invasion and migration of prostate cancer cells, which may be an important factor affecting the microenvironment of prostate cancer ( 42 , 43 ).Takahashi T et al. found that methylation of ZNF695 is an important factor affecting the chemotherapeutic resistance of esophageal squamous cell carcinoma ( 44 ).…”
Section: Discussionmentioning
confidence: 99%
“…According to Eschrich et al [6], the lower quartile of RSI was pre-de ned as the cut-off point for dividing patients into the RS and RR groups. The calculating formula of RRRI [9]…”
Section: Validation Of the Two Existing Radiosensitivity Signaturesmentioning
confidence: 99%
“…The 31-GS is developed by Kim's group, NCI-60 cancer cell panel (including prostate cancer) was analyzed for genes whose expression correlates with SF2 [8]. The RRRI is developed by Ke et al [9], and has been validated through TCGA and GSE cohort for its good biochemical recurrence predicting ability. Notably, there are no overlapping genes between the two radiosensitivity predictive indexes.…”
Section: Introductionmentioning
confidence: 99%
“…Currently, the recommended management method for BCR by European Association of Urology is mainly based on prostate-specific antigen doubling time (PSA-DT), Gleason score, International Society of Urological Pathology (ISUP) grade and interval from primary therapy to biochemical failure [ 15 ], but there are still defects in the process of clinical application. With the advent of next-generation sequencing, more and more biomarkers for the management of BCR based on transcriptomic data are identified from different perspectives [ 8 , 12 , 14 , 20 22 ]. Interestingly, radiomics attracts clinicians’ attention in PCa, such as prostate volume and other traits [ 23 , 24 ].…”
Section: Introductionmentioning
confidence: 99%